{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:34:24Z","timestamp":1792427664619,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04820-7","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:04:11Z","timestamp":1776474251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vonoprazan-amoxicillin dual therapy combined with probiotics for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Ye","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haocheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"9","key":"4820_CR1","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","volume":"71","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022;71(9):1724\u201362.","journal-title":"Gut"},{"issue":"5","key":"4820_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ijc.2910600502","volume":"60","author":"H M\u00f8ller","year":"1995","unstructured":"M\u00f8ller H, Heseltine E, Vainio H. Working group report on schistosomes, liver flukes and Helicobacter pylori. Int J Cancer. 1995;60(5):587\u20139. https:\/\/doi.org\/10.1002\/ijc.2910600502.","journal-title":"Int J Cancer"},{"issue":"6","key":"4820_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","volume":"8","author":"Y Li","year":"2023","unstructured":"Li Y, Choi H, Leung K, et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553\u201364. https:\/\/doi.org\/10.1016\/S2468-1253(23)00070-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"4820_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/gutjnl-2022-328965","volume":"72","author":"XZ Zhou","year":"2023","unstructured":"Zhou XZ, Lyu NH, Zhu HY, et al. Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention. Gut. 2023;72(5):855\u201369. https:\/\/doi.org\/10.1136\/gutjnl-2022-328965.","journal-title":"Gut"},{"issue":"9","key":"4820_CR5","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","volume":"119","author":"WD Chey","year":"2024","unstructured":"Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Off J Am Coll Gastroenterol| ACG. 2024;119(9):1730\u201353. https:\/\/doi.org\/10.14309\/ajg.0000000000002968.","journal-title":"Off J Am Coll Gastroenterol| ACG"},{"issue":"7","key":"4820_CR6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.14309\/ajg.0000000000002255","volume":"118","author":"PI Hsu","year":"2023","unstructured":"Hsu PI, Chen KY, Tai WC, et al. Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Helicobacter pylori infection in Taiwan: a multicenter, open-label, randomized trial. Am J Gastroenterol. 2023;118(7):1184\u201395. https:\/\/doi.org\/10.14309\/ajg.0000000000002255.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"4820_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","volume":"9","author":"TC Hong","year":"2024","unstructured":"Hong TC, El-Omar EM, Kuo YT, et al. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024;9(1):56\u201367. https:\/\/doi.org\/10.1016\/S2468-1253(23)00281-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"4820_CR8","doi-asserted-by":"publisher","first-page":"e12692","DOI":"10.1111\/hel.12692","volume":"25","author":"CP Gao","year":"2020","unstructured":"Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12692. https:\/\/doi.org\/10.1111\/hel.12692.","journal-title":"Helicobacter"},{"issue":"24","key":"4820_CR9","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","volume":"135","author":"L Zhou","year":"2022","unstructured":"Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135(24):2899\u2013910. https:\/\/doi.org\/10.1097\/CM9.0000000000002546.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"4820_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/MOG.0000000000000543","volume":"35","author":"C Scarpignato","year":"2019","unstructured":"Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol. 2019;35(4):344\u201355. https:\/\/doi.org\/10.1097\/MOG.0000000000000543.","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"4820_CR11","doi-asserted-by":"publisher","first-page":"e12970","DOI":"10.1111\/hel.12970","volume":"28","author":"J Hu","year":"2023","unstructured":"Hu J, Mei H, Su NY, et al. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China. Helicobacter. 2023;28(4):e12970. https:\/\/doi.org\/10.1111\/hel.12970.","journal-title":"Helicobacter"},{"key":"4820_CR12","doi-asserted-by":"publisher","first-page":"1108373952","DOI":"10.1177\/17562848231190976","volume":"16","author":"X Wang","year":"2023","unstructured":"Wang X, Teng G, Dong X, et al. Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial. Therap Adv Gastroenterol. 2023;16:1108373952. https:\/\/doi.org\/10.1177\/17562848231190976.","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"4820_CR13","doi-asserted-by":"publisher","first-page":"e13003","DOI":"10.1111\/hel.13003","volume":"28","author":"NY Su","year":"2023","unstructured":"Su NY, Shi Q, Mei H, et al. Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: a propensity score matching analysis. Helicobacter. 2023;28(5):e13003. https:\/\/doi.org\/10.1111\/hel.13003.","journal-title":"Helicobacter"},{"issue":"4Part-II","key":"4820_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.12669\/pjms.38.4.5436","volume":"38","author":"BF Zuberi","year":"2022","unstructured":"Zuberi BF, Ali FS, Rasheed T, et al. Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter pylori eradication: a randomized control trial. Pak J Med Sci. 2022;38(4Part-II):965\u20139. https:\/\/doi.org\/10.12669\/pjms.38.4.5436.","journal-title":"Pak J Med Sci"},{"issue":"2S Suppl","key":"4820_CR15","doi-asserted-by":"publisher","first-page":"396S","DOI":"10.1093\/jn\/130.2.396S","volume":"130","author":"RD Rolfe","year":"2000","unstructured":"Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000;130(2S Suppl):396S-402S. https:\/\/doi.org\/10.1093\/jn\/130.2.396S.","journal-title":"J Nutr"},{"issue":"1","key":"4820_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/advances\/nmy063","volume":"10","author":"J Plaza-Diaz","year":"2019","unstructured":"Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, et al. Mechanisms of action of probiotics. Adv Nutr. 2019;10(1):49\u201366. https:\/\/doi.org\/10.1093\/advances\/nmy063.","journal-title":"Adv Nutr"},{"key":"4820_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cytogfr.2020.10.004","volume":"57","author":"A Vincenzi","year":"2021","unstructured":"Vincenzi A, Goettert MI, Volken DSC. An evaluation of the effects of probiotics on tumoral necrosis factor (TNF-\u03b1) signaling and gene expression. Cytokine Growth Factor Rev. 2021;57:27\u201338. https:\/\/doi.org\/10.1016\/j.cytogfr.2020.10.004.","journal-title":"Cytokine Growth Factor Rev"},{"key":"4820_CR18","doi-asserted-by":"publisher","first-page":"110490","DOI":"10.1016\/j.foodres.2021.110490","volume":"147","author":"C Tang","year":"2021","unstructured":"Tang C, Kong L, Shan M, et al. Protective and ameliorating effects of probiotics against diet-induced obesity: a review. Food Res Int. 2021;147:110490. https:\/\/doi.org\/10.1016\/j.foodres.2021.110490.","journal-title":"Food Res Int"},{"issue":"5","key":"4820_CR19","doi-asserted-by":"publisher","first-page":"e12651","DOI":"10.1111\/hel.12651","volume":"24","author":"BG Zhou","year":"2019","unstructured":"Zhou BG, Chen LX, Li B, et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5):e12651. https:\/\/doi.org\/10.1111\/hel.12651.","journal-title":"Helicobacter"},{"issue":"6","key":"4820_CR20","doi-asserted-by":"publisher","first-page":"e12856","DOI":"10.1111\/hel.12856","volume":"26","author":"C Yang","year":"2021","unstructured":"Yang C, Liang L, Lv P, et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: a randomized double-blind placebo-controlled trial. Helicobacter. 2021;26(6):e12856. https:\/\/doi.org\/10.1111\/hel.12856.","journal-title":"Helicobacter"},{"key":"4820_CR21","doi-asserted-by":"publisher","unstructured":"Payne J, Bellmer D, Jadeja R, et al. The potential of bacillus species as probiotics in the food industry: a review. Foods 2024;13(15) https:\/\/doi.org\/10.3390\/foods13152444.","DOI":"10.3390\/foods13152444"},{"issue":"32","key":"4820_CR22","doi-asserted-by":"publisher","first-page":"e34787","DOI":"10.1097\/MD.0000000000034787","volume":"102","author":"G Men","year":"2023","unstructured":"Men G, Wang L, Lu X, et al. Can Enterococcus faecium prevent NEC in preterm infants?: a systematic review and meta-analysis. Medicine (Baltimore). 2023;102(32):e34787. https:\/\/doi.org\/10.1097\/MD.0000000000034787.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"4820_CR23","doi-asserted-by":"publisher","first-page":"12874","DOI":"10.1038\/s41598-019-49415-3","volume":"9","author":"L Wu","year":"2019","unstructured":"Wu L, Wang Z, Sun G, et al. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep. 2019;9(1):12874. https:\/\/doi.org\/10.1038\/s41598-019-49415-3.","journal-title":"Sci Rep"},{"issue":"1","key":"4820_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40121-020-00372-9","volume":"10","author":"B Tang","year":"2021","unstructured":"Tang B, Tang L, Huang C, et al. The effect of probiotics supplementation on gut microbiota after helicobacter pylori eradication: a multicenter randomized controlled trial[J]. Infect Dis Ther. 2021;10(1):317\u201333. https:\/\/doi.org\/10.1007\/s40121-020-00372-9.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"4820_CR25","doi-asserted-by":"publisher","first-page":"2356279","DOI":"10.1080\/19490976.2024.2356279","volume":"16","author":"MN Rahman","year":"2024","unstructured":"Rahman MN, Barua N, Tin M, et al. The use of probiotics and prebiotics in decolonizing pathogenic bacteria from the gut; a systematic review and meta-analysis of clinical outcomes. Gut Microbes. 2024;16(1):2356279. https:\/\/doi.org\/10.1080\/19490976.2024.2356279.","journal-title":"Gut Microbes"},{"issue":"11","key":"4820_CR26","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1128\/AAC.45.11.3156-3161.2001","volume":"45","author":"IV Pinchuk","year":"2001","unstructured":"Pinchuk IV, Bressollier P, Verneuil B, et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother. 2001;45(11):3156\u201361. https:\/\/doi.org\/10.1128\/AAC.45.11.3156-3161.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"4820_CR27","doi-asserted-by":"publisher","unstructured":"Yang H, Lin Y, Ma Y, et al. Screening probiotics for anti-helicobacter pylori and investigating the effect of probiotics on patients with helicobacter pylori infection. Foods 2024;13(12) https:\/\/doi.org\/10.3390\/foods13121851.","DOI":"10.3390\/foods13121851"},{"issue":"11","key":"4820_CR28","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.14309\/ajg.0000000000003351","volume":"120","author":"DD Casas","year":"2025","unstructured":"Casas DD, Alcedo J, Lafuente M, et al. Probiotics prescribed with Helicobacter pylori eradication therapy in Europe: usage pattern, effectiveness, and safety. results from the European registry on Helicobacter pylori management (Hp-EuReg). Am J Gastroenterol. 2025;120(11):2644\u201359. https:\/\/doi.org\/10.14309\/ajg.0000000000003351.","journal-title":"Am J Gastroenterol"},{"key":"4820_CR29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.clnesp.2024.11.016","volume":"65","author":"M Tanashat","year":"2025","unstructured":"Tanashat M, Abuelazm M, Abouzid M, et al. Efficacy of probiotics regimens for Helicobacter pylori eradication: a\u00a0systematic review, pairwise, and network meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2025;65:424\u201344. https:\/\/doi.org\/10.1016\/j.clnesp.2024.11.016.","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"4820_CR30","doi-asserted-by":"publisher","first-page":"10069","DOI":"10.1038\/s41598-024-59399-4","volume":"14","author":"Z Yang","year":"2024","unstructured":"Yang Z, Zhou Y, Han Z, et al. The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses. Sci Rep. 2024;14(1):10069. https:\/\/doi.org\/10.1038\/s41598-024-59399-4.","journal-title":"Sci Rep"},{"issue":"14","key":"4820_CR31","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.26355\/eurrev_202307_33144","volume":"27","author":"XF Bai","year":"2023","unstructured":"Bai XF, Tian D, Wang TY, et al. The impact of probiotics on gut microbiota in the eradication of Helicobacter pylori infection: a systematic review[J]. Eur Rev Med Pharmacol Sci. 2023;27(14):6736\u201343. https:\/\/doi.org\/10.26355\/eurrev_202307_33144.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"4820_CR32","doi-asserted-by":"publisher","first-page":"e163743","DOI":"10.1371\/journal.pone.0163743","volume":"11","author":"M Lu","year":"2016","unstructured":"Lu M, Yu S, Deng J, et al. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS ONE. 2016;11(10):e163743. https:\/\/doi.org\/10.1371\/journal.pone.0163743.","journal-title":"PLoS ONE"},{"issue":"1","key":"4820_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41368-022-00212-1","volume":"15","author":"X Yuan","year":"2023","unstructured":"Yuan X, Zhou F, Wang H, et al. Systemic antibiotics increase microbiota pathogenicity and oral bone loss. Int J Oral Sci. 2023;15(1):4. https:\/\/doi.org\/10.1038\/s41368-022-00212-1.","journal-title":"Int J Oral Sci"},{"issue":"1","key":"4820_CR34","doi-asserted-by":"publisher","first-page":"e13040","DOI":"10.1111\/hel.13040","volume":"29","author":"BG Zhou","year":"2024","unstructured":"Zhou BG, Jiang X, Ding YB, et al. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2024;29(1):e13040. https:\/\/doi.org\/10.1111\/hel.13040.","journal-title":"Helicobacter"},{"issue":"9","key":"4820_CR35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/17474124.2018.1503946","volume":"12","author":"LR Lopetuso","year":"2018","unstructured":"Lopetuso LR, Napoli M, Rizzatti G, et al. Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol. 2018;12(9):899\u2013906. https:\/\/doi.org\/10.1080\/17474124.2018.1503946.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"4820_CR36","doi-asserted-by":"publisher","first-page":"100975","DOI":"10.1016\/j.lanmic.2024.100975","volume":"6","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhang ZY, Wang F, et al. Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025;6(3):100975. https:\/\/doi.org\/10.1016\/j.lanmic.2024.100975.","journal-title":"Lancet Microbe"},{"key":"4820_CR37","doi-asserted-by":"publisher","first-page":"110676","DOI":"10.1016\/j.foodres.2021.110676","volume":"149","author":"M Marzorati","year":"2021","unstructured":"Marzorati M, Van den Abbeele P, Bubeck S, et al. Treatment with a spore-based probiotic containing five strains of Bacillus induced changes in the metabolic activity and community composition of the gut microbiota in a SHIME(R) model of the human gastrointestinal system. Food Res Int. 2021;149:110676. https:\/\/doi.org\/10.1016\/j.foodres.2021.110676.","journal-title":"Food Res Int"},{"issue":"1","key":"4820_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1099\/jmm.0.076430-0","volume":"64","author":"Z Zhou","year":"2015","unstructured":"Zhou Z, Gong S, Li XM, et al. Expression of Helicobacter pylori urease B on the surface of Bacillus subtilis spores. J Med Microbiol. 2015;64(1):104\u201310. https:\/\/doi.org\/10.1099\/jmm.0.076430-0.","journal-title":"J Med Microbiol"},{"issue":"7","key":"4820_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1139\/cjm-2023-0014","volume":"69","author":"X Li","year":"2023","unstructured":"Li X, Kong R, Wang J, et al. The formation mechanism of Bacillus subtilis biofilm surface morphology under competitive environment. Can J Microbiol. 2023;69(7):251\u201361. https:\/\/doi.org\/10.1139\/cjm-2023-0014.","journal-title":"Can J Microbiol"},{"key":"4820_CR40","doi-asserted-by":"publisher","unstructured":"Viazis N, Argyriou K, Kotzampassi K, et al. A four-probiotics regimen combined with a standard helicobacter pylori-eradication treatment reduces side effects and increases eradication rates. Nutrients 2022;14(3) https:\/\/doi.org\/10.3390\/nu14030632.","DOI":"10.3390\/nu14030632"},{"issue":"6","key":"4820_CR41","doi-asserted-by":"publisher","first-page":"107600","DOI":"10.1016\/j.ijantimicag.2025.107600","volume":"66","author":"YH Liu","year":"2025","unstructured":"Liu YH, Zhang J, Li DH, et al. The impact of probiotics on Helicobacter pylori eradication with bismuth quadruple therapy: a systematic review and meta-analysis[J]. Int J Antimicrob Agents. 2025;66(6):107600. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107600.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"4820_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/00365529850166185","volume":"33","author":"S Sj\u00f6stedt","year":"1998","unstructured":"Sj\u00f6stedt S, Sagar M, Lindberg G, et al. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin[J]. Scand J Gastroenterol. 1998;33(1):39\u201343.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"4820_CR43","doi-asserted-by":"publisher","first-page":"e12781","DOI":"10.1111\/hel.12781","volume":"26","author":"X Song","year":"2021","unstructured":"Song X, Cai C, Jin Q, et al. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: a systematic review and meta-analysis[J]. Helicobacter. 2021;26(2):e12781. https:\/\/doi.org\/10.1111\/hel.12781.","journal-title":"Helicobacter"},{"issue":"2","key":"4820_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2478\/v10039-008-0043-7","volume":"53","author":"DB Namiot","year":"2008","unstructured":"Namiot DB, Leszczy\u0144ska K, Namiot Z, et al. Smoking and drinking habits are important predictors of Helicobacter pylori eradication. Adv Med Sci. 2008;53(2):310\u20135. https:\/\/doi.org\/10.2478\/v10039-008-0043-7.","journal-title":"Adv Med Sci"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04820-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:58:20Z","timestamp":1779929900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04820-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4820"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04820-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a prospective, multicenter, double-blind, randomized controlled trial. It was approved by the Medical Ethics Committee of Nanjing First Hospital Affiliated to Nanjing Medical University (Approval No. KY20240123-20). The study was conducted in accordance with the Declaration of Helsinki. All participants were fully informed of potential risks and provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}